MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2012.12.015

Медицинская библиотека · Vaccine · 2012

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.

Wijnans Leonoor, Lecomte Coralie, de Vries Corinne, Weibel Daniel, Sammon Cormac, Hviid Anders, Svanström Henrik, Mølgaard-Nielsen Ditte, Heijbel Harald, Dahlström Lisen Arnheim, Hallgren Jonas, Sparen Par, Jennum Poul, Mosseveld Mees, Schuemie Martijn, van der Maas Nicoline, Partinen Markku, Romio Silvana, Trotta Francesco, Santuccio Carmela, Menna Angelo, Plazzi Giuseppe, Moghadam Keivan Kaveh, Ferro Salvatore, Lammers Gert Jan, Overeem Sebastiaan, Johansen Kari, Kramarz Piotr, Bonhoeffer Jan, Sturkenboom Miriam C J M

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

In August 2010 reports of a possible association between exposure to AS03 adjuvanted pandemic A(H1N1)pdm09 vaccine and occurrence of narcolepsy in children and adolescents emerged in Sweden and Finland. In response to this signal, the background rates of narcolepsy in Europe were assessed to rapidly provide information for signal verification.

METHODS

We used a dynamic retrospective cohort study to assess the narcolepsy diagnosis rates during the period 2000-2010 using large linked automated health care databases in six countries: Denmark, Finland, Italy, the Netherlands, Sweden and the United Kingdom.

RESULTS

Overall, 2608 narcolepsy cases were identified in almost 280 million person years (PY) of follow up. The pooled incidence rate was 0.93 (95% CI: 0. 90-0.97) per 100,000 PY. There were peaks between 15 and 30 year of age (women>men) and around 60 years of age. In the age group 5-19 years olds rates were increased after the start of pandemic vaccination compared to the period before the start of campaigns, with rate ratios (RR) of 1.9 (95% CI: 1.1-3.1) in Denmark, 6.4 (95% CI: 4.2-9.7) in Finland and 7.5 (95% CI: 5.2-10.7) in Sweden. Cases verification in the Netherlands had a significant effect on the pattern of incidence over time.

CONCLUSIONS

The results of this incidence study provided useful information for signal verification on a population level. The safety signal of increased narcolepsy diagnoses following the start of the pandemic vaccination campaign as observed in Sweden and Finland could be observed with this approach. An increase in narcolepsy diagnoses was not observed in other countries, where vaccination coverage was low in the affected age group, or did not follow influenza A(H1N1)pdm09 vaccination. Patient level analyses in these countries are being conducted to verify the signal in more detail.

Для цитирования: Wijnans Leonoor, Lecomte Coralie, de Vries Corinne, Weibel Daniel, Sammon Cormac, Hviid Anders, Svanström Henrik, Mølgaard-Nielsen Ditte, Heijbel Harald, Dahlström Lisen Arnheim, Hallgren Jonas, Sparen Par, Jennum Poul, Mosseveld Mees, Schuemie Martijn, van der Maas Nicoline, Partinen Markku, Romio Silvana, Trotta Francesco, Santuccio Carmela, Menna Angelo, Plazzi Giuseppe, Moghadam Keivan Kaveh, Ferro Salvatore, Lammers Gert Jan, Overeem Sebastiaan, Johansen Kari, Kramarz Piotr, Bonhoeffer Jan, Sturkenboom Miriam C J M. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.. Vaccine. 2012. DOI: 10.1016/j.vaccine.2012.12.015.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.